Paratek Pharmaceuticals News

Keyword Search

Date Title  
Oct 17, 2019
Paratek Withdraws European Marketing Authorization Application for Oral and Intravenous NUZYRA in Skin Infections and Pneumonia
Oct 01, 2019
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Sep 25, 2019
Paratek Pharmaceuticals Presenting New Data from NUZYRA® (Omadacycline) Development Program at IDWeek 2019
Sep 09, 2019
Paratek Mourns Passing of Co-founder Dr. Stuart Levy
Sep 04, 2019
Paratek Pharmaceuticals to Present at the 21st Annual H.C. Wainwright Global Investment Conference
Sep 03, 2019
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Aug 30, 2019
The Lancet Infectious Diseases Publishes Results from Paratek’s Phase 3 Oral only Dosing Study of NUZYRA® (omadacycline) for Skin Infections
Aug 26, 2019
Paratek Pharmaceuticals to Present at Robert W. Baird’s 2019 Global Healthcare Conference
Aug 06, 2019
Paratek Pharmaceuticals Generates Net Revenues of $2.0 Million in the Second Quarter of 2019
Aug 01, 2019
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)